Physician profile
Danielle D Antosh
NPI 1578711495
$8,252.24
in general payments reported to CMS, 2019-2025
42 companies · $1,470 in 2025
The $1,470 reported for 2025 was more than what 77% of Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) providers received nationally (typical 2025 total: $413).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,224 · 2020: $721 · 2021: $913 · 2022: $1,346 · 2023: $1,156 · 2024: $1,422 · 2025: $1,470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,504 · Consulting Fee: $544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,503.99 |
| Consulting Fee | $543.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,954.92 | 2019-2025 | Solyx Sis System, Axonics, Upsylon |
| Coloplast Corp | $1,035.33 | 2019-2025 | |
| Abbvie INC. | $867.90 | 2019-2025 | Botox |
| Bayer Healthcare Pharmaceuticals INC. | $425.45 | 2020-2023 | |
| Axonics, INC. | $408.33 | 2020-2023 | Axonics |
| Medtronic, INC. | $367.06 | 2023-2025 | Interstim, V-Loc 180, Truclear |
| C. R. Bard, INC. & Subsidiaries | $300.00 | 2020 | |
| Sumitomo Pharma America, INC. | $236.62 | 2023-2025 | Gemtesa, Myfembree |
| Dentsply Ih INC. | $180.78 | 2022-2024 | Lofric |
| Astellas Pharma US INC | $169.25 | 2022-2025 | Veozah |
| Therapeuticsmd, INC. | $128.91 | 2019-2022 | |
| Ethicon US, LLC | $126.18 | 2021-2025 | Dermabond Prineo, Surgicel Nu-Knit, Surgiflo Hemostatic Matrix |
| Pacira Pharmaceuticals Incorporated | $105.21 | 2020-2022 | |
| Pfizer INC. | $83.65 | 2021-2022 | |
| Caldera Medical, INC | $52.45 | 2023 | Desara |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $51.70 | 2022 | |
| Coopersurgical, INC. | $45.07 | 2019-2024 | Paragard T 380a |
| Bluewind Medical | $45.04 | 2025 | Revi |
| Allergan, INC. | $44.40 | 2019 | |
| Abbott Laboratories | $43.64 | 2022 | |
| Merck Sharp & Dohme LLC | $43.57 | 2019-2025 | Bridion |
| Daiichi Sankyo INC. | $41.04 | 2022 | |
| Renovia INC | $39.60 | 2019 | |
| Applied Medical Resources Corporation | $39.60 | 2024 | |
| Evofem Biosciences, INC. | $38.81 | 2021-2025 | Solosec, Phexx, Phexxi |
| Hologic Sales and Service, LLC | $38.01 | 2022-2025 | Omni Hysteroscope, Fluent Fluid Management System, Myosure Tissue Removal Device |
| Exeltis, USA INC. | $34.17 | 2021-2022 | |
| Heron Therapeutics, INC. | $32.95 | 2023-2024 | Zynrelef |
| Myovant Sciences INC. | $30.88 | 2021-2022 | |
| Tela Bio, INC. | $28.76 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Avion Pharmaceuticals | $27.03 | 2019-2020 | |
| Kerecis Limited | $26.91 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Mycovia Pharmaceuticals, INC. | $25.58 | 2023 | Vivjoa |
| Mimedx Group, INC. | $21.84 | 2024 | |
| Exact Sciences Corporation | $20.85 | 2025 | Cologuard Collection Kit |
| Amag Pharmaceuticals, INC. | $19.92 | 2019 | |
| Meditrina | $19.18 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $13.50 | 2019 | |
| Amgen INC. | $13.40 | 2024 | Evenity, Prolia |
| Sage Therapeutics, LLC | $12.63 | 2020 | |
| Lupin INC. | $12.12 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$80.50 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Antosh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.